

# Chronic kidney disease

4<sup>th</sup> years


**Mohammad Hassan Al-thnaibat**

# Outline

- Basics about the kidney
- Kidney functions
- GFR (estimation versus measurement)
- Pathophysiology of kidney disease
- CKD definition/ stages
- Epidemiology/Jordan
- Manifestation
- Complication
- Management (headlines)



# Kidney functions



- Regulation of fluid, pH, BP (short term = RAAS or long term = blood volume) The renin-angiotensin-aldosterone system

$K^+$ ,  $Na^+$ ,  $PO_4^{2-}$ ,  $Ca^{+2}$

- Homeostasis of electrolytes


- Endocrine (3 hormones RAAS, activation of Vitamin D, Erythropoietin 85%) Paracrine (PG E2, NO)

\* metabolism of many hormones can occur in kidney like insulin → insulin metabolism in CKD patients become slower. insulin build up → hypoglycemia

- Clearance: Excretion (endogenous or exogenous waste)

↳ end result of metabolism For example - metabolism of fat → CO<sub>2</sub> - metabolism of protein → nitrogenous waste product like urea.

- Gluconeogenesis 10% (fasting)



\* paracrine = Fibrinolysis





# Other filtration marker (exogenous)

## BOX 1

### Examples of Common Glomerular Filtration Markers

#### Radionuclides

- Inulin labeled with carbon 14 ( $^{14}\text{C}$ -inulin)
- **Technetium** Tc 99m diethylenetriaminepentaacetic acid ( $^{99\text{m}}\text{Tc}$ -DTPA)
- Chromium Cr 51 ethylenediaminetetraacetic acid ( $^{51}\text{Cr}$ -EDTA)

#### Nonradionuclides

- Iodinated
  - Ionic: iothalamate
  - Nonionic: iohexol, iopamidol
- Noniodinated
  - Inulin
  - Creatinine (endogenous or exogenously administered)

perfect / ideal Filtration marker  
→ freely filtered, exogenous, not metabolized, not secreted, not reabsorbed, not reabsorbed in urine, reflect in filtration.

→ not metabolized, not secreted, not reabsorbed, not reabsorbed in urine, reflect in filtration.

→ inulin clearance is used to reflect in filtration.

# CKD definition

Kidney Disease Outcomes Quality Initiative (KDOQI)

- Progressive irreversible loss of kidney functions
- Before 2002 (KDOQI): chronic renal failure
- Structural or functional abnormalities of the kidneys for >3 months, with or without decreased GFR < 60.
- NICE – UK 2008 : stage 3 a and b
- KDIGO 2012: A1-A3

المرحلة  
انقسام  
5 stages  
التقسيم  
GFR

هذا انما يعرف في GFR < 60  
This is CKD  
more than 3 months  
GFR  
This is not CKD until  
Find structural or  
Functional abnormalities.

address  
additional  
classification -  
to 5 stages  
based on  
albumin  
in urine

Structural → obstruction, cyst, small kidney, single kidney  
↳ with volume overload.

Functional → proteinuria, haematuria, metabolic acidosis, electrolyte disturbance  
due to kidney disease even if GFR more than 60%

# Pathophysiology

→ There are common  
pathway between  
different disease.

- Started by initiating injury
- Recruit inflammatory cell
- Release growth factor (balance between good and bad)
- Metalloproteinase, PA (cut the collagen)
- RAAS system activation: Ag II pro fibrotic

Transforming  
Factors

→  
\* Stimulate  
Fibrosis  
deposition

# CKD stages

\* albumin  $4\text{mg/dl}$  albumine in the Blood

من انفق من Protein ← Size barrier  
من انفق من Protein ← charge barrier

albumin  $11\text{g/dl}$   
The progression will be more Rapid

higher albumin in the urine → higher Risk of Cardiovascular disease  
← more coronary artery disease  
← more atherosclerosis

		Albuminuria categories (mg/g creatinine)		
		A1	A2	A3
		< 30	30–300	> 300
GFR categories (ml/min x 1.73 m <sup>2</sup> )	G1	≥ 90	*	
	G2	60–89		
	G3a	45–59		
	G3b	30–44		
	G4	15–29		
G5	< 15			
G5 D/T		Kidney failure		Usually defined by KRT

من انفق من Protein ←

(moderately increases) microproteinuria

Severely have albuminuria "proteinuria" detect by dipstick

detect dipstick is for 300


most complicated with GFR < 45

End Stage Renal disease

من انفق من Protein ←

# Epidemiology

- 10% of the adult population around the world have CKD stages 1–5
- Registration and diagnosis (variable between countries)
- found that approximately 31% of the individuals (at high risk) had unrecognised CKD eGFR < 90.
- 7% of the present sample had an eGFR of
- Mortality is higher than non CKD



# Risk factors

- Individuals with any of the following attributes are at high risk for CKD and could benefit from screening:
  - 1- age more than 60 years
  - 2- Diabetes mellitus (DM)
  - 3- Hypertension (HTN)
  - 4- Family history of kidney diseases

# Leading causes of CKD

- 1- Diabetes
  - 2- Hypertension
  - 3- Obstructive nephropathy (kidney stones, BPH)
  - 4- Kidney diseases (TIN, GN, ADPKD, recurrent UTI and pyelonephritis)
  - 5- Renovascular diseases → Renal artery stenosis  
Fibromuscular dysplasia (FMD)
  - 6- Some medications - for example, NSAIDs, Heavy metals
  - 7- Fetal developmental problem → Reflux → Diabetes
  - 8- Infections like Hep C and HIV, Malaria and yellow fever
  - 9- Illegal substance abuse - such as heroin or cocaine.
- Injury - a sharp blow or physical injury to the kidney

Vesicoureteral reflux (VUR) is a condition in which urine flows backward from the bladder to one or both ureters and sometimes to the kidneys. VUR is most common in infants and young children. Most children don't have long-term problems from VUR.





- **Hematological**

- Anemia *No erythropoietin*

- Bleeding: platelets dysfunction ( due to uremia )

- Infection: WBC dysfunction due to uremia

- CVS: CAD, HF, LVH, arrhythmia, pericarditis

- RS: pulmonary edema

*تفسيارية  
القول  
يسا  
تسببها البول*

- GI: N/V, ulcer, uremic fetor

*From CKD  
or underlying cause  
like DM*

- Neuro: encephalopathy, peripheral neuropathy, restless leg syndrome

2  
0 Urea by itself is not toxin to the tissue  
But its marker

- **Skin**


- Earthy color → accumulation of nitrogenous waste product.
- Pruritus
- Petechiae, ecchymosis
- Nail changes

# Uremic Frost

Whitish color on skin ← الصبيح

Frost

زهر




→ Earthy  
Color



→ Lindsay's nail → white/brown "half-and-half" nail occur in CKD



half and  
half  
nail  
due to  
uremic  
toxin  
and  
hypo albuminemia





# Investigation

- Urea/Cr *For diagnosis*  
*Stages*  
*Follow up*  
*adjust medication*
- Urinalysis and quantification of proteinuria (A1, A2 OR A3);
- Electrolytes; hyperkalaemia and acidosis, Calcium, phosphate, parathyroid hormone; Albumin
- Full blood count ( $\pm$  Fe, ferritin, folate, B12);
- Lipids, glucose  $\pm$  HbA1c;
- Renal ultrasound: size, asymmetry, cyst
- Hepatitis and HIV serology
- ECG *For hyperkalaemia*
- SPEP, serological test *serum protein electrophoresis*

*significant difference more than 0.5 cm  $\rightarrow$  renal vascular disease*

*features = ecogenicity*

*in general CKD  $\rightarrow$  lead to small kidney*

*what CKD that cause large kidney*

- DM*
- polycystic kidney disease*
- amyloidosis*
- HIV*
- obstructive nephropathy (some times)*

*light chain*

*To diagnosis MM*

*multiple myeloma*

*ES for CKD*

*patient came with renal failure*

*SLE + vasculitis*

# Management

- Acute versus chronic (baseline)
- Reversibility
- Retard progression
- Treat complication
- Prepare for renal replacement therapy

chronic  
acute above chronic  
acute

To slow progression


anemia + hyperparathyroidism

Previous

avoid nephrotoxic  
control BP

RRT







# Treat the cause

- GN
- Pyelonephritis
- AIN
- Obstruction ✓
- Renovascular disease

allergic  
interstitial  
nephritis

# Progression

# How I can slow the progression?

most important slides \*

- BP → control BP our target → 140/90  
IF there is proteinuria → 130/80
- Glycemic control → control sugar also helping
- RAAS blocker → ACEIs, ARBs even if it lower GFR  
But on long term it tend to slow progression.
- SGLT2 inhibitors
- Stop smoking
- Diet: protein, salt, phosphate, K
- Exercise 30 mint daily
- Obesity
- Acidosis  $\text{HCO}_3^- < 22$
- Uric acid ?
- Dyslipidemia

Nat. glucose cotransport in PCT → increase glucose in the urine.  
new oral hypoglycemic agent  
use in type 2 mainly  
decrease proteinuria, protect the kidney, protect kidney progression.  
beneficial to slow progression

increases GFR acutely → But on long term not affect kidney function.  
SGLT2 inhibitors → progression → if we control  $\text{HCO}_3^-$  to be higher than 22 progression should be treated by sodium bicarbonate  
if it below 22 should be treated by sodium bicarbonate  
control it will be help.

If patient has CKD → high protein diet will increase (fast) the progression.

دواء  
 ١٠٠٪  
 ١٠٠٪

should be adjusted according to GFR.

**Table 33-4 Drug Dosages in Chronic Kidney Disease**

Major Dosage Reduction	Minor or No Reduction	Avoid Usage
<b>Antibiotics</b>		
Aminoglycosides	Erythromycin	
Penicillin	Nafcillin	Nitrofurantoin
Cephalosporins	Clindamycin	Nalidixic acid
Sulfonamides	Chloramphenicol	Tetracycline
Vancomycin	Isoniazid, rifampin	
Quinolones	Amphotericin B	
Fluconazole	Aztreonam, tazobactam	
Acyclovir, ganciclovir	Doxycycline	
Foscarnet		
Imipenem		
<b>Others</b>		
Digoxin	Antihypertensives	Aspirin
Procainamide	Benzodiazepines	Sulfonylureas
H <sub>2</sub> antagonists	Quinidine	Lithium carbonate
Meperidine	Lidocaine	Acetazolamide
Codeine	Spirolactone	NSAIDs
Propoxyphene	Triamterene	Phosphate-containing bowel-preps

# 1. Cockcroft-Gault

Equation  
(mL/min) → not best, not used for medical dose adjustment

most accurate  
Not to classify the patient

$$CCr = \frac{(140 - \text{age}) \times \text{LBW [kg]}}{\text{Cr [mg/dL]} \times 72}$$

For women Multiply by 0.85

Other endogenous markers

# 2. MDRD study equation

(mL/min/1.73 m<sup>2</sup>)

$$GFR = 186.3 \times (SCr)^{-1.154} \times (\text{Age})^{-0.203}$$

Multiply by 0.742 for women

Multiply by 1.21 for African ancestry

# 3. CKD-EPI equation

حالياً  
المستعملين  
في جدول

ما يستعملوا  
في  
night  
من نظام  
من الجدول  
من الجدول

$$GFR = 141 \times \min(SCr/\kappa)^{\alpha} \times \max(SCr/\kappa)^{-1.209} \times 0.993^{\text{age}}$$

Multiply by 1.018 for women

Multiply by 1.159 for African ancestry


κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of SCr/κ or 1, & max indicates the maximum of SCr/κ or 1

# Complication

- **Treat anemia target (Hb: 10-11)**
- **Secondary hyperparathyroidism** ( by **vitamin D & Calcium** to correct phosphate actually ( ~~calcium-based phosphate binder~~ ) or ( Sevelamer / renagel ( non calcium-based phosphate binder) in case of high calcium)
- **CV disease** ( aspirin and statins)

PH = normal???

to decrease PTH  
 phosphate binder  
 to correct  $PO_4^-$   
 مع زيادة الفوسفات  
 في الدم  
 GI absorption  
 ↓  
 stool



# RRT

Renal  
replacement  
therapy

- Transplant
- Hemodialysis
- Peritoneal dialysis
- Artificial kidney
- Animal kidney ?

\* survival

\* quality of life

\* causes of death